NBDF/ LinkedIn
Aug 31, 2025, 07:31
Avatrombopag Shows Promise for Pediatric Immune Thrombocytopenia in Late-Stage Global Trial: NBDF
National Bleeding Disorders Foundation shared on LinkedIn:
“Promising news for children and adolescents living with immune thrombocytopenia (ITP). A late-stage global trial shows avatrombopag, an oral treatment already approved for adults, can significantly improve platelet counts and reduce bleeding symptoms in pediatric patients, offering a potential new treatment option for an underserved population.
Learn more about the study results and what they could mean for pediatric ITP care in The Lancet Haematology.”
Stay updated with Hemostasis Today.
-
Dec 9, 2025, 23:37Thomas Reiser: Renew Your ISTH Membership for 2025
-
Dec 9, 2025, 10:17Laura Vater: Admitting You Don’t Know Something Actually Helps People Trust You More
-
Dec 9, 2025, 09:06Maria Elisa Mancuso on NXT007 Prophylaxis in People With Haemophilia A
-
Dec 9, 2025, 09:00Cedric Hermans Presenting FRONTIER2 Data on Mim8 in Adolescents and Adults with Haemophilia A
-
Dec 9, 2025, 08:42Muhammad Awidi: IV Iron During Acute Infection Shows Improved Outcomes
-
Dec 9, 2025, 08:35Haseena MS: MAR Oncology and Hematology Invites New Research
-
Dec 9, 2025, 08:26Akshay Kumar Chopra: 3 Years as a Part of KMC Manipal
-
Dec 9, 2025, 08:07William Aird: Understanding Polycythemia
-
Dec 9, 2025, 08:02Amy H. Huang: Our Work on Bone Health in Myeloma Has Been Recognized with ASH Abstract Achievement Award